Global Vaccine Adjuvants Market is valued at approximately USD1.62 billion in 2022 andis anticipated to grow with a healthy growth rate of more than 2.3%duringthe forecast period 2023-2030.Adjuvants are the ingredients that are added to the vaccinations to increase effectiveness of the vaccine and improve its response. The expansion of the Vaccine Adjuvants Market is due to factors such as the increasing incidence of infectious diseases, growing geriatric population and rising awareness towards health and immunization. The awareness towards vaccination and immunization regarding the prevention of infectious diseases such as HIV and tuberculosis (TB) has gradually increased over a period of time. according to Centers for Disease Control and Prevention, there were 39 million people in the world who were suffering with HIV and this number is expected to reduce by 2% due to rising number of vaccine prevalence. Furthermore, according to World Health Organization, approximately 10.6 million people suffered with Tuberculosis (TB) around the globe. The continuous increase in the number of patients of infectious diseases lead to the rise in health awareness campaigns and immunization programs to reduce the number by using the preventive measures. Moreover, rising healthcare facilities and advancements in formulations are the opportunities through which the Vaccine Adjuvants Market can grow. However, the high cost of production of development may hinder the expansion of the Vaccine Adjuvants Market throughout the forecast period of 2020-2030. The key regions considered for the Global Vaccine Adjuvants Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa.North America dominated the market in 2022 due to factors such as an increase in investments inR&D and a rise in severe diseases. Consequently, vaccination against both acute and chronic diseases becomenecessary.Middle East & Africa areexpected to grow significantly overthe forecast perioddue to factors such as constantly enhancing medical facilities, which include the availability of medications and increasing financing for research and development to meet the massive unfulfilled needs. This is projected to raise the market share of Vaccine Adjuvants in the particular region. Major market player included in this report are: GlaxoSmithKline plc. Novavax, Inc. Adjuvance Technologies, Inc. SPI Pharma Agenus, Inc. CSL Limited InvivoGen AstrazenecaCroda International Plc Pfizer Inc. Recent Developments in the Market:  In May 2023, GSK plc declared that the US Food and Drug Administration approved Arexvy for the treatment of Respiratory Syncytial Virus (RSV) -related Lower Respiratory Tract Disease (LRTD) in patients 60 years of age and older. This is the first ever RSV immunization which is licensed for older people worldwide.  In March 2022, Croda International Plc confirmed the partnership with Statens Serum Institute. They mayproduce and commercialise a variety of patented cationic adjuvants, CAF which was developed by SSI. Global Vaccine Adjuvants Market Report Scope:  Historical Data –2020 - 2021  Base Year for Estimation – 2022  Forecast period - 2023-2030  Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends  Segments Covered - Type, Application, Administration, Region  Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa  Customization Scope - Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope* The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study. The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporatespotential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below: By Type: Pathogen Adjuvant emulsion Particulate Combination Others By Application: Infectious diseases Cancer Others By Administration: Oral Intradermal Intranasal Intramuscular Others By Region: North America U.S. Canada Europe UK Germany France Spain Italy ROE Asia Pacific China India Japan Australia South Korea RoAPAC Latin America Brazil Mexico Middle East & Africa Saudi Arabia South Africa Rest of Middle East & Africa